MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,447,831
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
1,394,569
1,435,135
2,924,607.5*
2,131,444
General and administrative
1,222,974
1,836,817
2,121,189*
1,898,397
Total operating expenses
2,617,543
3,271,952
5,045,796.5
4,029,841
Loss from operations
-2,617,543
-3,271,952
-5,045,796.5*
-4,029,841
Gain on remeasurement of warrant liabilities
0
0
114,045*
-27,816
Interest expense
2,935
6,653
2,299*
2,605
Interest income
176,319
89,354
188,445*
59,103
Other expense, net
-1,040
-3,390
-20,024*
-6,774
Total other income, net
172,344
79,311
280,167*
21,908
Loss before provision for income taxes
-2,445,199
-3,192,641
-4,765,629.5*
-4,007,933
Provision for income taxes
2,632
3,346
2,698*
2,840
Net loss
-2,447,831
-3,195,987
-4,768,327.5
-4,010,773
Basic EPS
-0.19
-0.46
0.043
-0.06
Basic Average Shares
13,208,816
7,022,945
-111,649,942
72,685,740
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$2,447,831
(59.56%↑ Y/Y)
Interest income
$176,319
(671.74%↑ Y/Y)
Loss before
provision for income taxes
-$2,445,199
(59.55%↑ Y/Y)
Provision for income taxes
$2,632
(-66.91%↓ Y/Y)
Total other income,
net
$172,344
(530.70%↑ Y/Y)
Interest expense
$2,935
(-38.82%↓ Y/Y)
Other expense, net
-$1,040
(43.78%↑ Y/Y)
Loss from operations
-$2,617,543
(56.90%↑ Y/Y)
Total operating
expenses
$2,617,543
(-56.90%↓ Y/Y)
Research and development
$1,394,569
(-62.56%↓ Y/Y)
General and
administrative
$1,222,974
(-47.92%↓ Y/Y)
Buy us a coffee
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)